<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19277103</article-id><article-id pub-id-type="pmc">2648636</article-id><article-id pub-id-type="doi">10.1155/2008/824036</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Radiation Therapy in Addition to Gross Total Resection of Retroperitoneal Sarcoma Results in Prolonged Survival: Results from a Single Institutional Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zagar</surname><given-names>Timothy M.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shenk</surname><given-names>Robert R.</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Julian A.</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Harpp</surname><given-names>Deb</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kunos</surname><given-names>Charles A.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abdul-Karim</surname><given-names>Fadi W.</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>William C.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seo</surname><given-names>Yuji</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kinsella</surname><given-names>Timothy J.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 4</sup></xref><xref ref-type="aff" rid="I4"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Radiation Oncology, Case Medical Center, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106, USA</aff><aff id="I2"><sup>2</sup>Department of Surgery, Case Medical Center, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106, USA</aff><aff id="I3"><sup>3</sup>Department of Pathology, Case Medical Center, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106, USA</aff><aff id="I4"><sup>4</sup>Department of Radiation Oncology, School of Medicine, Case Western Reserve University, Biomedical Research Building, Room 326, 2109 Adelbert Road, Cleveland, OH 44106, USA</aff><author-notes><corresp id="cor1">*Timothy J. Kinsella: <email>timothy.kinsella@case.edu</email></corresp><fn fn-type="other"><p>Recommended by Ralph R. Weichselbaum</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>824036</elocation-id><history><date date-type="received"><day>9</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Timothy M. Zagar et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>					<italic>Purpose</italic>. Typical treatment of retroperitoneal sarcomas (RPSs) is surgery with or without radiation therapy for localized disease.  With surgery alone, local failure rates are as high as 90%; this led to radiation therapy playing an important role in the treatment of RPSs. <italic>Methods</italic>. Thirty-one patients with retroperitoneal sarcoma treated with gross total resection and radiation therapy make up this retrospective analysis. Nineteen were treated preoperatively and 12 postoperatively (median dose, 59.4 Gy)&#x02014;sixteen also received intraoperative radiation therapy (IORT) (median dose, 11 Gy).  Patients were followed with stringent regimens, including frequent CT scans of the chest, abdomen, and pelvis. <italic>Results</italic>. With a median follow-up of 19 months (range 1&#x02013;66 months), the 2-year overall survival (OS) rate is 70% (median, 52 months).  The 2-year locoregional control (LRC) rate is 77% (median, 61.6 months).  The 2-year distant disease free survival (DDFS) rate is 70% (median not reached).  There were no differences in radiation-related acute and late toxicities among patients treated pre- versus postoperatively, whether with or without IORT. <italic>Conclusions</italic>. Compared to surgery alone, neoadjuvant or adjuvant radiation therapy offers patients with RPS an excellent chance for long-term LRC, DDS, and OS.  The integration of modern treatment planning for external beam radiation therapy and IORT allows for higher doses to be delivered with acceptable toxicities.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Retroperitoneal  sarcomas (RPSs) makeup  a minority of soft tissue sarcomas (STSs) diagnosed in the United States. In 2008, it is estimated that 10 390 people will be diagnosed with an STS; of these, approximately20%, or 2080, will occur in the retroperitoneum [<xref ref-type="bibr" rid="B1">1</xref>]. RPSs pose difficult diagnostic and therapeuticproblems for physicians treating them. As a result of their location, sarcomas that arise in this area can growto extremely large sizes (typically &#x0003e;10 cm) before causing symptoms. Their large masses may encompass criticalanatomic structures, significantly decreasing the rate of complete surgical resectability[<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>]. Only approximately half of RPSsare surgically resectable. Withoutadjuvant therapy, the risk of local recurrence ranges from 68% to more than 90%at 10 years [<xref ref-type="bibr" rid="B5">5</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>]. The prospect of adjuvantradiation therapy to &#x0201c;sterilize&#x0201d; positive surgical margins and/or minimal grossresidual disease has been vital in the treatment of RPSs. Additionally, preoperative radiation therapyis often used in an attempt to improve resectability.</p><p>There hasbeen no published randomized trial for preoperative versus postoperativeradiation therapy in patients with RPS, as there has been for soft tissuesarcomas of the extremity [<xref ref-type="bibr" rid="B8">8</xref>], largely because of the paucity of cases. As such, there is no consensus as to thesequencing, or even the need for radiation therapy for that matter. Radiation therapy has been given in thepreoperative setting [<xref ref-type="bibr" rid="B9">9</xref>&#x02013;<xref ref-type="bibr" rid="B12">12</xref>], in the hopes of converting a technicallyunresectable RPS to being resectable. Ithas also been given in the preoperative [<xref ref-type="bibr" rid="B13">13</xref>] and postoperative setting withconcurrent chemotherapy [<xref ref-type="bibr" rid="B14">14</xref>]. It canalso be given in the postoperative setting to help control any residualdisease, be it gross or microscopic [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B19">19</xref>]. Finally, radiation therapy can be given inthe intraoperative setting either with electrons from a linear accelerator orwith brachytherapy, both of which have been shown to increase local control [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>&#x02013;<xref ref-type="bibr" rid="B20">20</xref>].</p><p>At our institution, preoperativeradiation therapy with or without intraoperative radiation therapy (IORT) hasbeen utilized for large, potentially difficult-to-resect RPSs. Radiation therapy is recommended in the postoperativeadjuvant setting in patients who had surgery prior to initial referral, or forsmaller RPSs that our surgeons feel they can completely resect without havingto sacrifice too much normal anatomy for the sake of achieving a gross totalresection (GTR). We report one of thelargest single institution cohorts of patients with RPS treated with modernradiation therapy techniques, including a subset direct comparison betweenthose patients treated pre- versus postoperatively, to elucidate anydifferences in both outcome and toxicities.</p></sec><sec sec-type="section" id="sec2"><title>2. Materials and Methods</title><sec id="subsec2.1"><title>2.1. Patients</title><p>Between August 2000 and April 2008, 29consecutive adult patients with a histologic diagnosis of retroperitonealsarcoma and 2 patients with recurrent/persistent intraabdominal aggressive fibromatosis(desmoid tumor) were treated with at least one modality of radiation therapy at Case Medical Center in UniversityHospitals. All patients werepresented to the biweekly multidisciplinary sarcoma tumor board prior totreatment at our institution. Data werecollected retrospectively from paper charts and electronic medical recordsafter approval by our Cancer Center Review Board and our Institutional ReviewBoard.</p></sec><sec id="npsubsec2.2"><title>2.2. Treatment Regimens</title><sec id="subsubsec2.2.1"><title>2.2.1. Pre- and Postoperative External Beam Radiotherapy</title><p>Radiation therapy planning utilizingstandard computed tomography (CT)-guided 3-dimensional conformal techniques wasroutinely performed, typically with 4 to 7 fields used. As thetechniques of intensity modulated (IMRT) and image-guided radiation therapy(IGRT) utilizing TomoTherapy (Madison, Wis, USA) became available in 2004, they were utilized asper the physician's discretion. Allradiation treatment planning was performed by a senior radiation oncologist(TJK).</p></sec><sec id="subsubsec2.2.2"><title>2.2.2. Intraoperative Radiation Therapy (IORT)</title><p>When clinically indicated, IORT wasadministered via a Mobetron linear accelerator with electron energies of 6 to12 MeV, prescribed to the 90% isodose line (Intraop Medical, Inc., Sunnyvale, Calif, USA). After surgical resection of the RPS, a flat or beveled cylindrical cone(5&#x02013;10 cm) anchoredby a Bookwalter surgical clamp (Codman and Shurtleff, Inc., Raynham, Mass, USA)was placed by both the surgeon and radiation oncologist over areas at high riskof residual microscopic to minimal gross disease. No patients were treated with IORT for unresectabledisease. Dose-limiting normal tissuesthat were in the desired IORT bed, if mobile, were physically moved out of thefield&#x02014;if they wereimmobile, typically 3 half value layer lead wafers were used for shielding. The technique of IORT and surgical approachesto minimize acute and late IORT-related normal tissue toxicities are previouslydetailed [<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec id="subsubsec2.2.3"><title>2.2.3. Surgery</title><p>A gross total resection (GTR) wasachieved when the surgeon was able to resect all areas of visible disease inthe operating room&#x02014;a subtotalresection (STR) was performed when there was any amount of gross residualdisease left behind. An <italic>en bloc</italic>resection of the tumor mass and expendible involved normal tissues wasattempted in all patients. Microscopicmargin status was not routinely reported, but was assumed to be positive alongsoft tissue, bone, and vascular margins in the retroperitoneum.</p></sec><sec id="subsubsec2.3.4"><title>2.2.4. Follow-Up</title><p>Patients were followed up by theirtreating radiation oncologist after completing radiation every 3 months for thefirst year, every 4 months for the 2nd year, every 6 months for the 3rd and 4thyears, then annually, with a contrast enhanced CT of the chest, abdomen, andpelvis, and full labs with each visit. Other ancillary studies were performed as clinically indicated.</p></sec><sec id="subsubsec2.3.5"><title>2.2.5. Normal Tissue Toxicity Analyses</title><p>Acute (1&#x02013;90 days afterradiation therapy commencement) and chronic (&#x0003e;90 days) toxicities weregraded according to the Radiation Therapy Oncology Group (RTOG) acute and lateradiation morbidity scoring criteria [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec id="subsubsec2.2.6"><title>2.2.6. Definition of Treatment Outcomes and Statistical Considerations</title><p>The primary endpoints of this study werelocoregional control (LRC), distant disease-free survival (DDFS), and overallsurvival (OS). A locoregional failurewas defined as any tumor recurrence within the abdominal/retroperitonealcavity, including within radiation portals. Distant metastases (typically to liver and/or lung) were determined byCT examinations with or without subsequent histopathologic confirmation. OS, DDFS, and LRC were calculated from thefirst day of radiation therapy administration. The patients were censored at either their last follow-up, if theyremained alive and/or disease free, or the date of their local or distantfailure or death. The Kaplan-Meiermethod was used to compute LRC, DDFS, and OS [<xref ref-type="bibr" rid="B24">24</xref>]. Cox models were used for multivariateanalysis of prognostic factors [<xref ref-type="bibr" rid="B25">25</xref>]. Chisquare and Fisher's exact tests were utilized for categorical variables and mediantests were utilized to analyze the continuous variables to compare patient groupstreated pre- versus postoperatively [<xref ref-type="bibr" rid="B26">26</xref>]. All measures tests were analyzed with statistical software (SPSS 12.0,SPSS, Inc, Chicago, Ill, USA), with a 2-sided alpha level of 0.05 regarded asstatistically significant.</p></sec></sec></sec><sec sec-type="section" id="sec3"><title>3. Results</title><sec id="subsec3.1"><title>3.1. Patient and Treatment Characteristics</title><p>Twenty-nine consecutive patients withbiopsy proven retroperitoneal sarcoma and 2 patients with intraabdominalfibromatosis (desmoid tumor) were treated and closely followed over this 8+year period, for a median of 19 months (range 1&#x02013;66 months). The 2 patients with large intraabdominaldesmoid tumors were included in this analysis due to the highly aggressivenature of their lesions&#x02014;in fact, onepatient had positive lymph nodes at the time of surgical resection. Females made up the majority (65%) ofpatients, and Caucasians accounted for the overwhelming majority (90%). Most frequently, patients presented witheither pain or some type of vague abdominal discomfort, or unintentional weightloss (<xref ref-type="table" rid="tab1">Table 1</xref>). Overall, 26 (84%) patientswere able to have a gross total resection of their RPSs; 15 (79%) of thepatients were treated preoperatively and 11 (92%) of the patients were treatedpostoperatively. Patients treatedpostoperatively generally had smaller tumors (&#x02264;10 cm) at presentation. When separated into sequencing of treatment, 19(61%) patients were treated preoperatively (median dose 59.4 Gy, range 36.8&#x02013;63.4 Gy), withthe goal of improving the likelihood of achieving gross total resection; onepatient was palliated for her SVC syndrome, which was her presenting symptom. Twelve (39%) patients were treated in thepostoperative setting (median 59.4 Gy, range 54&#x02013;68.4 Gy) (<xref ref-type="table" rid="tab2">Table 2</xref>). Both groups were well matched with respect topatient characteristics, pathology, grade, clinical stage, histology, andextent of surgical resection. However, theonly statistically significant difference between the groups was the use ofIORT and IMRT. Thirteen (68%) patients weretreated with preoperative EBRT received IORT, compared to only 3 (25%) patientswho received IORT followed by postoperative EBRT, based on the recommendationsof the multidisciplinary sarcoma tumor board (<italic>P</italic> = .03, <xref ref-type="table" rid="tab2">Table 2</xref>). Eight (67%) patients treated withpostoperative EBRT were treated with IMRT/IGRT versus only 2 (11%) patients inthe preoperative group, based on the availability of TomoTherapy (<italic>P</italic> = .003).</p><sec id="subsubsec3.1.1"><title>3.1.1. Locoregional Control</title><p>Overall, the 31 patients have amedian locoregional control rate (LRC) of 61.6 months, with a 2-year LRC rate of77%   (SE +/&#x02212; 18%) (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>). Twopatients in the preoperative group and 1 patient in the postoperative groupdeveloped a locoregional failure as their first site of failure. There was no statistically significantdifference in LRC rates in patients treated pre- versus postoperatively (<italic>P</italic> = .79) (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref>). The use of IORTdid not have an impact on LRC (<italic>P</italic> = .550) (<xref ref-type="table" rid="tab3">Table 3</xref>).</p></sec><sec id="subsubsec3.1.2"><title>3.1.2. Distant Metastases</title><p>The median distant disease-freesurvival (DDFS) has not yet been achieved, with a 2-year DDFS of 70%   (SE +/&#x02212; 18%)(<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>). All 7 patients who developedmetastatic disease did so within the first 14 months of beginning radiationtherapy (median 4.8 months, range 4.2&#x02013;14.2 months). Treatment for metastases was physiciandependent&#x02014;all were offeredchemotherapy. One patient underwentmultiple video-assisted thorascopic (VATS) resections of his pulmonarymetastases, while one other received palliative radiation therapy to her lungmetastases. Four patients in thepreoperative group and 2 patients in the postoperative group developed distantmetastases as their first site of failure&#x02014;two patients inthe postoperative group developed synchronous distant and locoregionalfailures. There was no statisticallysignificant difference in DDFS rates in patients treated pre- versuspostoperatively (<italic>P</italic> = .73), whether with or without IORT (<italic>P</italic> = .42); see <xref ref-type="fig" rid="fig2">Figure 2(b)</xref>and <xref ref-type="table" rid="tab3">Table 3</xref>.</p></sec><sec id="subsec3.2"><title>3.2. Overall Survival</title><p>The median overall survival for thispatient cohort was 52 months, with a 2-year OS rate of 70%   (SE +/&#x02212; 19%) (<xref ref-type="fig" rid="fig3">Figure 3(a)</xref>). Nine patients died duringfollow-up, with 8 of these directly attributable to retroperitoneal sarcoma. The other death occurred in a patient whosuffered from a complicated postoperative course, including intractableclostridium difficile colitis. At lastfollow-up (5.8 months), she was free of both local and recurrent disease, but shewas ultimately lost to follow-up. Therewas no statistically significant difference in DDFS rates in patients treatedpre- versus postoperatively (<italic>P</italic> = .14), whether with or without IORT (<italic>P</italic> = .77); see <xref ref-type="fig" rid="fig3">Figure 3(b)</xref> and <xref ref-type="table" rid="tab3">Table 3</xref>.</p></sec></sec><sec id="subsec3.3"><title>3.3. Prognostic Factors for LRC, DDFS, and OS</title><p>There were two trends that approachedstatistical significance; those patients treated postoperatively had a trend tohave lesions  &#x02264;10 cm (<italic>P</italic> = .07), and were more likely to present withrecurrent disease (<italic>P</italic> = .08). Inour cohort of patients, after controlling for whether patients were treated inthe preoperative or postoperative setting, none of the commonly citedcharacteristics had a statistically significant impact on LRC, DDFS, or OS, onmultivariate analysis (<xref ref-type="table" rid="tab3">Table 3</xref>).</p><sec id="subsubsec3.3.1"><title>3.3.1. Toxicity</title><p>Most patients (90%) completed theplanned course of radiation therapy without significant (&#x02265;grade 3) acuteeffects. Acute and late toxicities were similarbetween the pre- and postoperative groups (<xref ref-type="table" rid="tab4">Table 4</xref>). There were 3 grade 3-4 acute radiation-relatedtoxicities (all 3 in the preoperative group), and 17 grade 3-4 late toxicities(11 in the preoperative group, 6 in the postoperative group)&#x02014;no grade 5 treatment-relatedtoxicities occurred. The most common acute side effect seen, withalmost 90% of patients overall experiencing, was grade 1-2 gastrointestinalcomplaints, most commonly being nausea and/or diarrhea. These grade 1-2 toxicities responded toconservative medical treatment. Latetoxicities occurred less frequently and there were no statistically significantdifferences in late grade 3-4 toxicities between those patients treated pre-versus postoperatively (<xref ref-type="table" rid="tab4">Table 4</xref>). Onceagain, late GI toxicities were the most common type of a late side effect&#x02014;when theyoccurred, they were more often grade 3 to 4, including requiring emergencysurgery for small bowel obstruction related to adhesions (one patient each inthe preoperative and postoperative groups). There was one grade 1 (asymptomatic) jejunal stricture found at surgeryfor another reason, in a patient treated postoperatively, that was presumed tobe radiation-related. One patient whowas treated with postoperative radiation therapy for his second locoregionalfailure, and then preoperatively for his third locoregional failure, sufferedfrom chronic small bowel obstructions. The only fistula that was documented in our series occurred in a patientwho had 5 metachronous locoregional failures, and who was radiated preoperativelywith gross total resection of her fourth and later fifth locoregional failures.</p><p>A total of 16 patients reported grade1-2 pain or abdominal discomfort during radiation therapy&#x02014;11 in thepreoperative group and 5 in the postoperative group (<italic>P</italic> = .47). As these tumors are often symptomatic withpain at presentation, a multifactorial cause of the pain/discomfort waslikely. Narcotics were used judiciouslyin these patients. Those patientstreated postoperatively had more frequent acute grade 1-2 genitourinary-relatedtoxicities, when compared to the preoperative cohort (<italic>P</italic> = .05). There was no statistically significantdifference in wound healing and/or infection in the two different cohorts&#x02014;3 patients in thepreoperative group and 1 patient treated postoperatively developed abscessesmore than 90 days after radiation that required drainage (<italic>P</italic> = .31). Radiation-induced menopause was seen in 3patients&#x02014;2 treatedpreoperatively, and one in the postoperative setting.</p></sec></sec></sec><sec sec-type="section" id="sec4"><title>4. Discussion</title><p>Feng et al. reported on a large group of85 patients with RPS radiated over a 20-year period [<xref ref-type="bibr" rid="B11">11</xref>]. Their 2-year LC, DDFS, and OS rates were 66%,62%, and 70%, compared to our 77%, 70%, and 70%, respectively. They were the first to report an apparentdose response relationship with adjuvant radiation therapy for RPS, with higherdoses ( &#x02265;55.8 Gy) being associated with improved LC, but with no effect onoverall survival [<xref ref-type="bibr" rid="B11">11</xref>]. Typically, doses of 45 Gy to 50.4 Gy have beenutilized in the preoperative setting for RPSs [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. Our 2-year rate of LRC may be, in fact, dueto the higher doses of radiation used (median dose, 59.4 Gy) which may have animpact on DDFS. We routinely used thishigher dose in the preoperative setting, as we have extrapolated from our owninstitution's data for extremity soft tissue sarcomas, with all patients&#x02014;both thosetreated pre- and postoperatively&#x02014;receiving amedian dose of 59.4 Gy [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>A direct comparison of treatmentoutcomes following combined surgery and radiation therapy for patients withretroperitoneal sarcomas is particularly difficult as there is no standardizeddefinition of what is a local failure. Somereports, like our study, define a local failure as any recurrence of disease inthe abdominal cavity, save the hepatic parenchyma [<xref ref-type="bibr" rid="B9">9</xref>]. Other reports use more stringent definitions and divide locoregional failureinto &#x0201c;central&#x0201d; (within the IORT field), &#x0201c;local&#x0201d; (if within the EBRTfield), &#x0201c;regional&#x0201d; (if in regional lymphatics), &#x0201c;peritoneal&#x0201d; (if seedingoccurred), and &#x0201c;distant&#x0201d; (if beyond the regional site) [<xref ref-type="bibr" rid="B10">10</xref>]. In our series, we had no central or localfailures. The predominant mode offailure was regional, but not within lymph nodes.</p><p>Our series reports a high rate ofgross total resections. Twenty-six (84%)patients&#x02014;fifteen treatedwith preoperative radiation, and 11 treated postoperatively&#x02014;were able toundergo a GTR. On presentation, 2patients were deemed by our surgeons to have technically unresectable tumors. Both were treated with preoperative radiation&#x02014;one subsequentlyhad his tumor respond enough to undergo a GTR. Both patients with technically unresectable disease eventually developedpulmonary metastases. The patient whohad a GTR also had 2 separate metastectomies of lung metastases and remained without evidenceof further recurrent disease 29 months after initial treatment.</p><p>We advocate a stringent follow-upregimen for these patients. The NationalComprehensive Cancer Network (NCCN) guidelines recommend following patientsevery 3 to 6 months for the first 2 to 3 years with CTs of the abdomen andpelvis (with consideration of chest imaging) [<xref ref-type="bibr" rid="B28">28</xref>]. We routinely recommend CTs also of the chestevery 3 and 4 months for the first 2 years, as we have seen that all patientswho develop metastatic disease do so within the first 15 months of therapy. This regimen allows for identification ofpatients who might be candidates for initial metastectomy for oligometastasesor systemic therapy at an earlier time for multiple pulmonary lesions. While there may be an element of lead-timebias with this imaging regimen, we believe that, with early identification ofmetastases, we can prolong disease-free intervals, while the distant diseaseburden is still manageable.</p><p>Many patients with RPS ultimatelyfail distantly and systemic therapies have not proven to be efficacious. One potential future direction in thetreatment of RPSs mirrors the targeted therapy revolution currently occurringwith various malignancies. Fifteen of 31patients' tumors were stained for the presence of CD-117 (c kit) and of the 5patients tumors that demonstrated varying degrees of positivity byimmunohistochemistry, one patient received 4 months of imatinib mesylate in thepreoperative setting during her radiation therapy. However, repeat immunohistochemistry forCD-117 was negative on the resected residual mass and no post-operativeimatinib mesylate was given. Thispatient remains clinically and radiographically disease-free at 40 months.</p><p>As our results demonstrate, if apatient is to develop metastatic disease, he is at highest risk within the first years and ahalf after treatment. Chemotherapy mighthave a role in the early setting, and not just be reserved for patients whohave already developed metastatic disease. Pisters et al. evaluatedthe use of doxorubicin concurrent with radiation therapy, and found that onecould escalate to a dose of 50.4 Gy safely [<xref ref-type="bibr" rid="B13">13</xref>]. However, Glenn et al. from the NationalCancer Institute reported increased acute toxicities with the use ofpostoperative triple chemotherapy (including doxorubicin) during radiotherapyin patients with resectable RPSs, without an overall survival benefit [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Overall, the acute toxicitiesassociated with the modern day use of pre- or postoperative radiation therapy weremild. Thirty of 31 patients completedradiation therapy as prescribed. Thepatient who did not complete radiation therapy had initially presented withmetastatic disease and small bowel obstruction secondary to his large tumor. He ultimately had palliative bypass surgeryand succumbed to his distant disease. Therewere three grade 3-4 acute radiation-related toxicities (all 3 in the preoperativegroup), and six grade 3-4 late GI toxicities (3 in the preoperative group, 3 inthe postoperative group), with the formation of only one treatment relatedbowel fistula. For comparison, Peterson et al. reported 12 cases of grade 3or higher GI complications in her series of 87 (43 with primary disease, and 44with recurrent disease) patients with RPS; 7 of these patients had fistulaformation [<xref ref-type="bibr" rid="B10">10</xref>]. In our series, 6patients (4 in the preoperative group, 2 in the postoperative group) alsoexperienced late grade 3-4 infectious complications, requiring drainage of retroperitonealabscesses and prolonged intravenous antibiotics. Grading radiation-related toxicities inpatients with RPS is especially difficult, and even more so in patients whopresent with extremely large and/or recurrent tumors. Often times multiple abdominal surgeries havebeen performed&#x02014;a fact alone thatdramatically raises the incidence of late toxicities. There is some toxicity that must be assumedwhen treating these large tumors&#x02014;withoutradiation, the risk of local recurrence is unacceptably high, and thelikelihood of similar toxicities secondary to tumor growth alone is similarly high.</p><p>The use of IORT has been shown toincrease local control, without adding significantly to acute and latetoxicities from surgery [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. However, peripheral neuropathy has beendocumented with the clinical and experimental use of IORT to doses of  &#x02265;20 Gy [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>]. Importantly, the incidence ofIORT-related peripheral neuropathy is not increased with the use of externalbeam radiation therapy [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>]. In ourcohort of patients, only one patient experienced a late grade 2 neuropathy. This patient received preoperative radiation andIORT for her fourth and fifth locoregional failures. IORT doses of 10 to 12 Gy as utilized in ourstudy almost uniformly preclude the development of late neurologic sequelae. However, IORT did not appear to significantlyimpact LRC, DDFS, or OS in our patients.</p><p>The American College  of Surgeons Oncology Group attempted a phase III trial, which randomizedpatients with resectable RPS to surgery alone versus preoperative radiationtherapy followed by surgical resection [<xref ref-type="bibr" rid="B31">31</xref>]. However, even with excellent planning and organization, the study wasclosed because of slow accrual. Thus, adefinitive answer from a prospective randomized trial regarding the efficacy ofpreoperative radiation will not be available in the foreseeable future. Future studies/trials may need to include randomizationof patients to surgery alone, preoperative radiation with surgery, and surgerywith postoperative radiation therapy. Addingchemotherapy in the neo- or adjuvant setting, so as to reduce the risk ofdeveloping metastatic disease, can also be considered.</p><p>In summary, high dose (59.4 Gy) preoperativeor postoperative radiation therapy is safe and efficacious in the treatment ofRPSs. Based upon our experience, werecommend the consideration of either neoadjuvant or adjuvant radiation inpatients with retroperitoneal sarcoma, as well as the possibility of IORT ifthere is a high likelihood of residual microscopic or minimal gross disease atthe time of surgical resection. We alsorecommend routine use of follow-up chest CT scans along with abdominal andpelvic CT scans. Some patients who initiallypresent with locally recurrent disease are able to have long-term disease freeintervals when treated with radiation therapy at the time of initial recurrence. However, as patients who receive radiationmore than one time for their RPS recurrences, the severity of adverse relatedevents increases. Further research needsto be done, including the development of better systemic agents to combat thesedifficult-to-treat tumors.</p></sec></body><back><ack><title>Acknowledgment</title><p>This work is supported, inpart, by the University Radiation Medicine Foundation.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="other"><collab>American Cancer Society</collab><comment>Cancer facts and figures, 2008, <ext-link ext-link-type="uri" xlink:href="http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf">http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf</ext-link>.</comment></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storm</surname><given-names>FK</given-names></name><name><surname>Mahvi</surname><given-names>DM</given-names></name></person-group><article-title>Diagnosis and management of retroperitoneal soft-tissue sarcoma</article-title><source><italic>Annals of Surgery</italic></source><year>1991</year><volume>214</volume><issue>1</issue><fpage>2</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">2064467</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Catton</surname><given-names>CN</given-names></name><name><surname>O'Sullivan</surname><given-names>B</given-names></name><name><surname>Kotwall</surname><given-names>C</given-names></name><name><surname>Cummings</surname><given-names>B</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Fornasier</surname><given-names>V</given-names></name></person-group><article-title>Outcome and prognosis in retroperitoneal soft tissue sarcoma</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>1994</year><volume>29</volume><issue>5</issue><fpage>1005</fpage><lpage>1010</lpage></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malerba</surname><given-names>M</given-names></name><name><surname>Doglietto</surname><given-names>GB</given-names></name><name><surname>Pacelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Primary retroperitoneal soft tissue sarcomas: results of aggressive surgical treatment</article-title><source><italic>World Journal of Surgery</italic></source><year>1999</year><volume>23</volume><issue>7</issue><fpage>670</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">10390584</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>RR</given-names></name><name><surname>Donohue</surname><given-names>JH</given-names></name><name><surname>Mucha</surname><given-names>P</given-names><suffix>Jr.</suffix></name><name><surname>van Heerden</surname><given-names>JA</given-names></name><name><surname>Reiman</surname><given-names>HM</given-names></name><name><surname>Chen</surname><given-names>SP</given-names></name></person-group><article-title>Management of retroperitoneal sarcomas</article-title><source><italic>Surgery</italic></source><year>1989</year><volume>106</volume><issue>4</issue><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">2799648</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cody</surname><given-names>HS</given-names><suffix>III</suffix></name><name><surname>Turnbull</surname><given-names>AD</given-names></name><name><surname>Fortner</surname><given-names>JG</given-names></name><name><surname>Hajdu</surname><given-names>SI</given-names></name></person-group><article-title>The continuing challenge of retroperitoneal sarcomas</article-title><source><italic>Cancer</italic></source><year>1981</year><volume>47</volume><issue>9</issue><fpage>2147</fpage><lpage>2152</lpage><pub-id pub-id-type="pmid">7226108</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karakousis</surname><given-names>CP</given-names></name><name><surname>Velez</surname><given-names>AF</given-names></name><name><surname>Gerstenbluth</surname><given-names>R</given-names></name><name><surname>Driscoll</surname><given-names>DL</given-names></name></person-group><article-title>Resectability and survival in retroperitoneal sarcomas</article-title><source><italic>Annals of Surgical Oncology</italic></source><year>1996</year><volume>3</volume><issue>2</issue><fpage>150</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">8646515</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Sullivan</surname><given-names>B</given-names></name><name><surname>Davis</surname><given-names>AM</given-names></name><name><surname>Turcotte</surname><given-names>R</given-names></name><etal/></person-group><article-title>Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial</article-title><source><italic>The Lancet</italic></source><year>2002</year><volume>359</volume><issue>9325</issue><fpage>2235</fpage><lpage>2241</lpage></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JJ</given-names></name><name><surname>Catton</surname><given-names>CN</given-names></name><name><surname>O'Sullivan</surname><given-names>B</given-names></name><etal/></person-group><article-title>Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma</article-title><source><italic>Annals of Surgical Oncology</italic></source><year>2002</year><volume>9</volume><issue>4</issue><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">11986186</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>IA</given-names></name><name><surname>Haddock</surname><given-names>MG</given-names></name><name><surname>Donohue</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2002</year><volume>52</volume><issue>2</issue><fpage>469</fpage><lpage>475</lpage></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Griffith</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2007</year><volume>69</volume><issue>1</issue><fpage>103</fpage><lpage>110</lpage></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gieschen</surname><given-names>HL</given-names></name><name><surname>Spiro</surname><given-names>IJ</given-names></name><name><surname>Suit</surname><given-names>HD</given-names></name><etal/></person-group><article-title>Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2001</year><volume>50</volume><issue>1</issue><fpage>127</fpage><lpage>131</lpage></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pisters</surname><given-names>PWT</given-names></name><name><surname>Ballo</surname><given-names>MT</given-names></name><name><surname>Fenstermacher</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2003</year><volume>21</volume><issue>16</issue><fpage>3092</fpage><lpage>3097</lpage><pub-id pub-id-type="pmid">12915599</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glenn</surname><given-names>J</given-names></name><name><surname>Sindelar</surname><given-names>WF</given-names></name><name><surname>Kinsella</surname><given-names>T</given-names></name></person-group><article-title>Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum</article-title><source><italic>Surgery</italic></source><year>1985</year><volume>97</volume><issue>3</issue><fpage>316</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">3975851</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinsella</surname><given-names>TJ</given-names></name><name><surname>Sindelar</surname><given-names>WF</given-names></name><name><surname>Lack</surname><given-names>E</given-names></name><name><surname>Glatstein</surname><given-names>E</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1988</year><volume>6</volume><issue>1</issue><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">3275748</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sindelar</surname><given-names>WF</given-names></name><name><surname>Kinsella</surname><given-names>TJ</given-names></name><name><surname>Chen</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Intraoperative radiotherapy in retroperitoneal sarcomas: final results of a prospective, randomized, clinical trial</article-title><source><italic>Archives of Surgery</italic></source><year>1993</year><volume>128</volume><issue>4</issue><fpage>402</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">8457152</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoeckle</surname><given-names>E</given-names></name><name><surname>Coindre</surname><given-names>J-M</given-names></name><name><surname>Bonvalot</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group</article-title><source><italic>Cancer</italic></source><year>2001</year><volume>92</volume><issue>2</issue><fpage>359</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">11466691</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pierie</surname><given-names>J-PEN</given-names></name><name><surname>Betensky</surname><given-names>RA</given-names></name><name><surname>Choudry</surname><given-names>U</given-names></name><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Souba</surname><given-names>WW</given-names></name><name><surname>Ott</surname><given-names>MJ</given-names></name></person-group><article-title>Outcomes in a series of 103 retroperitoneal sarcomas</article-title><source><italic>European Journal of Surgical Oncology</italic></source><year>2006</year><volume>32</volume><issue>10</issue><fpage>1235</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">16919908</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Youssef</surname><given-names>E</given-names></name><name><surname>Fontanesi</surname><given-names>J</given-names></name><name><surname>Mott</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term outcome of combined modality therapy in retroperitoneal and deep-trunk soft-tissue sarcoma: analysis of prognostic factors</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2002</year><volume>54</volume><issue>2</issue><fpage>514</fpage><lpage>519</lpage></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pisters</surname><given-names>PWT</given-names></name><name><surname>Harrison</surname><given-names>LB</given-names></name><name><surname>Leung</surname><given-names>DHY</given-names></name><name><surname>Woodruff</surname><given-names>JM</given-names></name><name><surname>Casper</surname><given-names>ES</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name></person-group><article-title>Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1996</year><volume>14</volume><issue>3</issue><fpage>859</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">8622034</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>RJ</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kinsella</surname><given-names>TJ</given-names></name><name><surname>Eisenberg</surname><given-names>BL</given-names></name></person-group><article-title>Intraoperative radiotherapy in the multimodality approach to bone and soft tissue cancers</article-title><source><italic>Surgical Oncology Clinics of North America</italic></source><year>2003</year><volume>12</volume><issue>4</issue><fpage>1015</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">14989130</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sindelar</surname><given-names>WF</given-names></name><name><surname>Kinsella</surname><given-names>TJ</given-names></name></person-group><article-title>Normal tissue tolerance to intraoperative radiotherapy</article-title><source><italic>Surgical Oncology Clinics of North America</italic></source><year>2003</year><volume>12</volume><issue>4</issue><fpage>925</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">14989124</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>JD</given-names></name><name><surname>Stetz</surname><given-names>J</given-names></name><name><surname>Pajak</surname><given-names>TF</given-names></name></person-group><article-title>Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>1995</year><volume>31</volume><issue>5</issue><fpage>1341</fpage><lpage>1346</lpage></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Nonparametric estimation from incomplete observations</article-title><source><italic>Journal of the American Statistical Association</italic></source><year>1958</year><volume>53</volume><issue>282</issue><fpage>457</fpage><lpage>481</lpage></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DR</given-names></name></person-group><article-title>Regression models and life-tables</article-title><source><italic>Journal of the Royal Statistical Society. Series B</italic></source><year>1972</year><volume>34</volume><issue>2</issue><fpage>187</fpage><lpage>220</lpage></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA</given-names></name></person-group><article-title>On the interpretation of <italic>&#x003c7;</italic><sup>2</sup> from contingency tables, and the calculation of P</article-title><source><italic>Journal of the Royal Statistical Society. Series B</italic></source><year>1922</year><volume>85</volume><issue>1</issue><fpage>87</fpage><lpage>94</lpage></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunos</surname><given-names>C</given-names></name><name><surname>Colussi</surname><given-names>V</given-names></name><name><surname>Getty</surname><given-names>P</given-names></name><name><surname>Kinsella</surname><given-names>T</given-names></name></person-group><article-title>Intraoperative electron radiotherapy for extremity sarcomas does not increase acute or late morbidity</article-title><source><italic>Clinical Orthopaedics &#x00026; Related Research</italic></source><year>2006</year><issue>446</issue><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">16467624</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="other"><collab>National Comprehensive Cancer Network</collab><comment>NCCN Clinical Practice Guidelines in Oncology: Soft tissue sarcoma. V.1.2008, <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf">http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf</ext-link>.</comment></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinsella</surname><given-names>TJ</given-names></name><name><surname>Sindelar</surname><given-names>WF</given-names></name><name><surname>DeLuca</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Tolerance of peripheral nerve to intraoperative radiotherapy (IORT): clinical and experimental studies</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>1985</year><volume>11</volume><issue>9</issue><fpage>1579</fpage><lpage>1585</lpage></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinsella</surname><given-names>TJ</given-names></name><name><surname>DeLuca</surname><given-names>AM</given-names></name><name><surname>Barnes</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>W</given-names></name><name><surname>Terrill</surname><given-names>R</given-names></name><name><surname>Sindelar</surname><given-names>WF</given-names></name></person-group><article-title>Threshold dose for peripheral neuropathy following intraoperative radiotherapy (IORT) in a large animal model</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>1991</year><volume>20</volume><issue>4</issue><fpage>697</fpage><lpage>701</lpage></citation></ref><ref id="B31"><label>31</label><citation citation-type="other"><collab>National Cancer Institute</collab><comment>Phase III Randomized Study of Surgery With or Without Preoperative Radiotherapy in Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis, <ext-link ext-link-type="uri" xlink:href="http://www.cancer.gov/clinicaltrials/ACOSOG-Z9031">http://www.cancer.gov/clinicaltrials/ACOSOG-Z9031</ext-link>.</comment></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>(a) Locoregional control: all 31 patients. (b)Locoregional control: pre- versus postoperative EBRT (<italic>P</italic> = .79). EBRT =external beam radiation therapy.</p></caption><graphic xlink:href="JO2008-824036.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>(a) Distant disease free survival: all 31patients. (b) Distant disease free survival: pre- versus postoperative EBRT (<italic>P</italic> = .73). EBRT = external beam radiation therapy.</p></caption><graphic xlink:href="JO2008-824036.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>(a) Overall survival: all 31 patients. (b) Overall survival: pre- versuspostoperative EBRT (<italic>P</italic> = .14). EBRT = external beam radiation therapy.</p></caption><graphic xlink:href="JO2008-824036.003"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Patient and tumor characteristics (allpatients).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">No. of patients (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> Sex </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">11 (35%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">20 (65%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Age (range) </td><td align="center" rowspan="1" colspan="1">56 (20&#x02013;83)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Race </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="center" rowspan="1" colspan="1">28 (90%)</td></tr><tr><td align="left" rowspan="1" colspan="1">African American</td><td align="center" rowspan="1" colspan="1">3 (10%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> History of tobacco use </td><td align="center" rowspan="1" colspan="1">11 (35%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Family history of malignancy </td><td align="center" rowspan="1" colspan="1">7 (23%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">4 (13%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast and ovarian cancers</td><td align="center" rowspan="1" colspan="1">2 (6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sarcoma</td><td align="center" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Prior cancer </td><td align="center" rowspan="1" colspan="1">4 (13%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Breast</td><td align="center" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Melanoma</td><td align="center" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hodgkin's disease</td><td align="center" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Prior radiation </td><td align="center" rowspan="1" colspan="1">3 (10%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> TNM stage </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">T2bN0M0</td><td align="center" rowspan="1" colspan="1">25 (81%)</td></tr><tr><td align="left" rowspan="1" colspan="1">T2bN0M1</td><td align="center" rowspan="1" colspan="1">4 (13%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Desmoid</td><td align="center" rowspan="1" colspan="1">2 (6%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Grade </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">6 (19%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">6 (19%)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">17 (55%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> AJCC stage </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">10 (32%)</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">15 (48%)</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">4 (13%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Recurrent RPS </td><td align="center" rowspan="1" colspan="1">7 (23%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Pretreatment size of RPS (range) </td><td align="center" rowspan="1" colspan="1">10.5 cm (4.0&#x02013;20.0)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Histology </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Leiomyosarcoma</td><td align="center" rowspan="1" colspan="1">15 (48%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Liposarcoma</td><td align="center" rowspan="1" colspan="1">10 (32%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Myxoid</italic></td><td align="center" rowspan="1" colspan="1">3 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Dedifferentiated</italic></td><td align="center" rowspan="1" colspan="1">4 (13%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Desmoid</td><td align="center" rowspan="1" colspan="1">2 (6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Malignant fibrous histiocytoma</td><td align="center" rowspan="1" colspan="1">3 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Inflammatory myofibroblastic sarcoma</td><td align="center" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CD 117 staining </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Not done</td><td align="center" rowspan="1" colspan="1">16 (52%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">10 (32%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">5 (16%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Imatinib mesylate given</td><td align="center" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Symptoms at presentation </td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Pain/discomfort</td><td align="center" rowspan="1" colspan="1">20 (65%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight loss (range)</td><td align="center" rowspan="1" colspan="1">9 (31%) 10&#x02013;30 lbs</td></tr><tr><td align="left" rowspan="1" colspan="1">Early satiety/decreased appetite</td><td align="center" rowspan="1" colspan="1">6 (21%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">3 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Change in menses</td><td align="center" rowspan="1" colspan="1">2 (7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Small bowel obstruction</td><td align="center" rowspan="1" colspan="1">2 (7%)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Patient, tumor, and treatment characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Parameters </th><th align="center" rowspan="1" colspan="1"> Preoperative EBRT group (<italic>n</italic> = 19)</th><th align="center" rowspan="1" colspan="1"> Postoperative EBRT group (<italic>n</italic> = 12)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>   value </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> Gender </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">12 (63%)</td><td align="center" rowspan="1" colspan="1">8 (67%)</td><td align="center" rowspan="2" colspan="1"> 1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">7 (37%)</td><td align="center" rowspan="1" colspan="1">4 (33%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Age at presentation </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264;50 years</td><td align="center" rowspan="1" colspan="1">8 (42%)</td><td align="center" rowspan="1" colspan="1">2 (17%)</td><td align="center" rowspan="2" colspan="1">  .24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;50 years</td><td align="center" rowspan="1" colspan="1">11 (58%)</td><td align="center" rowspan="1" colspan="1">10 (83%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> AJCC stage </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">5 (26%)</td><td align="center" rowspan="1" colspan="1">5 (42%)</td><td align="center" rowspan="3" colspan="1">  .24</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">12 (63%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">2 (11%)</td><td align="center" rowspan="1" colspan="1">2 (17%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Grade </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3 (16%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td><td align="center" rowspan="3" colspan="1">  .66</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4 (21%)</td><td align="center" rowspan="1" colspan="1">2 (17%)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">12 (63%)</td><td align="center" rowspan="1" colspan="1">5 (42%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Tumor size </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x02264;10 cm</td><td align="center" rowspan="1" colspan="1">7 (37%)</td><td align="center" rowspan="1" colspan="1">9 (75%)</td><td align="center" rowspan="2" colspan="1">   .07</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x0003e;10 cm</td><td align="center" rowspan="1" colspan="1">12 (63%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Lesion presentation </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Primary</td><td align="center" rowspan="1" colspan="1">17 (89%)</td><td align="center" rowspan="1" colspan="1">7 (58%)</td><td align="center" rowspan="2" colspan="1">  .08</td></tr><tr><td align="left" rowspan="1" colspan="1">Recurrent</td><td align="center" rowspan="1" colspan="1">2 (11%)</td><td align="center" rowspan="1" colspan="1">5 (42%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Histology </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Leiomyosarcoma</td><td align="center" rowspan="1" colspan="1">9 (47%)</td><td align="center" rowspan="1" colspan="1">6 (50%)</td><td align="center" rowspan="3" colspan="1">  .72</td></tr><tr><td align="left" rowspan="1" colspan="1">Liposarcoma</td><td align="center" rowspan="1" colspan="1">7 (37%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">3 (16%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Extent resection </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">STR</td><td align="center" rowspan="1" colspan="1">4 (21%)</td><td align="center" rowspan="1" colspan="1">1 (8%)</td><td align="center" rowspan="2" colspan="1">  .62</td></tr><tr><td align="left" rowspan="1" colspan="1">GTR</td><td align="center" rowspan="1" colspan="1">15 (79%)</td><td align="center" rowspan="1" colspan="1">11 (92%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Organs removed </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">9 (47%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td><td align="center" rowspan="2" colspan="1">   .27</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">10 (53%)</td><td align="center" rowspan="1" colspan="1">9 (75%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Chemo</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">16 (84%)</td><td align="center" rowspan="1" colspan="1">9 (75%)</td><td align="center" rowspan="2" colspan="1">  .65</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">3 (16%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> IORT </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">6 (32%)</td><td align="center" rowspan="1" colspan="1">9 (75%)</td><td align="center" rowspan="2" colspan="1">   .03</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes (1 pt each arm had 2 fields)</td><td align="center" rowspan="1" colspan="1">13 (68%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Radiotherapy dose </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">EBRT median (range)</td><td align="center" rowspan="1" colspan="1">59.4 Gy (36.8&#x02013;63.4 Gy)</td><td align="center" rowspan="1" colspan="1">59.4 Gy (54&#x02013;68.4)</td><td align="center" rowspan="2" colspan="1">  .79</td></tr><tr><td align="left" rowspan="1" colspan="1">IORT median (range)</td><td align="center" rowspan="1" colspan="1">11 Gy (10&#x02013;12 Gy)</td><td align="center" rowspan="1" colspan="1">11 Gy (10&#x02013;12 Gy)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> IMRT </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">17 (89%)</td><td align="center" rowspan="1" colspan="1">4 (33%)</td><td align="center" rowspan="2" colspan="1">   .002</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">2 (11%)</td><td align="center" rowspan="1" colspan="1">8 (67%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Time to complete EBRT Median (range)</td><td align="center" rowspan="1" colspan="1">45 days(17&#x02013;90 days)</td><td align="center" rowspan="1" colspan="1">44 days(41&#x02013;55 days)</td><td align="center" rowspan="1" colspan="1">   .76</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Length of F/U Median (range)</td><td align="center" rowspan="1" colspan="1">22 months(0.6&#x02013;56.5 months)</td><td align="center" rowspan="1" colspan="1">13.05 months(1.4&#x02013;66.4 months)</td><td align="center" rowspan="1" colspan="1">   .55</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>EBRT = external beam radiation therapy; STR = subtotal resection; GTR = gross totalresection; IORT = intraoperative radiation therapy; IMRT = intensity modulatedradiation therapy; F/U = follow-up.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Cox regressionmultivariate analysis when controlled for pre- versus postoperative treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Locoregional control</th><th align="center" rowspan="1" colspan="1">Distant disease free survival</th><th align="center" rowspan="1" colspan="1">Overall survival</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .98</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .79</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .81</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .76</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .12</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .72</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .95</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .21</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .99</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .81</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .57</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .93</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor size</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .76</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .46</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .96</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary versus recurrent</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .60</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .27</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .65</td></tr><tr><td align="left" rowspan="1" colspan="1">Histology</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .70</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .53</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .92</td></tr><tr><td align="left" rowspan="1" colspan="1">GTR/STR</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .55</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .41</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .77</td></tr><tr><td align="left" rowspan="1" colspan="1">IORT</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .55</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .42</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .76</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemo</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .83</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .39</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .77</td></tr><tr><td align="left" rowspan="1" colspan="1">EBRT dose</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .79</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .28</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .60</td></tr><tr><td align="left" rowspan="1" colspan="1">Organ resected</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .85</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .34</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .66</td></tr></tbody></table><table-wrap-foot><fn><p>GTR = gross total resection; STR = subtotal resection; IORT = intraoperativeradiation therapy; EBRT = external beam radiation therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>RTOG acute and late toxicities of radiation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1">Preoperative EBRT group (<italic>n</italic> = 19)</th><th align="center" rowspan="1" colspan="1">Postoperative EBRT group (<italic>n</italic> = 12)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="center" colspan="4" rowspan="1"> Acute (&#x02264;90 days) </td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GI </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">16 (84%)</td><td align="center" rowspan="1" colspan="1">11 (92%)</td><td align="center" rowspan="2" colspan="1">  .70</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GU </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td><td align="center" rowspan="2" colspan="1"> .05</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Wound complications</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">1 (8%)</td><td align="center" rowspan="2" colspan="1">  .39</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Infection </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Skin </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">2 (11%)</td><td align="center" rowspan="1" colspan="1">1 (8%)</td><td align="center" rowspan="2" colspan="1">  1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Pain </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">11 (58%)</td><td align="center" rowspan="1" colspan="1">5 (42%)</td><td align="center" rowspan="2" colspan="1">  .47</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Neurologic </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">2 (11%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  .51</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Gynecologic </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="center" colspan="4" rowspan="1"> Late (&#x0003e;90 days) </td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GI </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">2 (17%)</td><td align="center" rowspan="2" colspan="1">  .51</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">3 (16%)</td><td align="center" rowspan="1" colspan="1">3 (25%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GU </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Wound complications </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">   1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Infection </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  .31</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">4 (21%)</td><td align="center" rowspan="1" colspan="1">2 (17%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Skin </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Pain </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Neurologic </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Gynecologic </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">   1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">2 (11%)</td><td align="center" rowspan="1" colspan="1">1 (8%)</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Lymphedema </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 1-2</td><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="2" colspan="1">  1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3-4</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td></tr></tbody></table><table-wrap-foot><fn><p>RTOG = Radiation therapy oncologygroup; EBRT = external beam radiation therapy; GI = gastrointestinal; GU =genitourinary.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>